Interview 12 Oct 2022 Boosting pharma’s falling productivity with AI in drug discovery The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael Nally, outlines the firm’s mission to tackle the trend by making drug discovery scalable. Over the decades, the pharma and biopharma industry has suffered a growing stagnation in productivity. According to a report from University College London in 2018, for […] October 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2022 How the alternative protein space aims to address food waste Food waste impacts the whole of society, including the field of alternative protein. Nick Cooney, managing partner of Lever VC, explains how companies and investors in the space aim to tackle the global problem. This week, the UN and its food security-focused arm, the Food and Agriculture Organization, celebrate the International Day of Awareness of […] September 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2022 Natural killer cells: a thriving frontier in allogeneic cell therapy Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […] September 27, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2022 Europe’s first lab-grown fish company Bluu Seafood is aiming for sustainability Overfishing is a global issue that negatively impacts the ecosystem and our access to fish protein. One solution to overfishing is producing fish products in the lab from harvested animal cells. This can help feed the world while using up fewer resources and without endangering wild fish populations. As the world’s population continues to grow, […] September 27, 2022 - 5 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Interview 26 Sep 2022 Rapid diagnostics are needed to tackle antimicrobial resistance As the antimicrobial resistance (AMR) crisis grows, bacterial infections are becoming harder to treat. Chris Lock, vice president of R&D at the mass spectrometry specialist SCIEX, discusses how rapid diagnostics can help doctors wield antimicrobial treatments more effectively. The AMR crisis is growing increasingly severe, resulting in superbugs that are able to shrug off multiple […] September 26, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 12 Sep 2022 Orchestrating the evolving cell therapy supply chain In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […] September 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 31 Aug 2022 How CDMOs keep pace with trends in advanced therapies Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO Lonza, sheds light on the latest trends in advanced therapies and how manufacturers are keeping up. In 2021, global funding going to cell and gene […] August 31, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 29 Aug 2022 Making a success out of technology transfer at UCLB Having a good relationship with the technology transfer office at your university can be key to creating a successful startup. Anne Lane, CEO of University College London’s (UCL’s) commercialization company UCLB, discusses recent successes and shares insights on how to advance new innovations. Anne Lane began her career as a scientist, completing a PhD at […] August 29, 2022 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 22 Aug 2022 Hiring practices are shifting as biotech goes digital Cloud computing is becoming increasingly prevalent as demand for global collaborations grows. Sajith Wickramasekara, founder and CEO of the cloud lab software provider Benchling, explains how this shift is affecting the labor market in the biotech industry. The biotech industry is becoming increasingly enmeshed with the world of digital technology, as companies search for ways […] August 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 19 Aug 2022 How re-engineering antibodies can prevent allergies The California startup IgGenix is aiming to re-engineer antibodies that mediate allergic responses into antibodies that can block this response. We spoke with IgGenix’s CEO Jessica Grossman and CTO Derek Croote to understand the potential of such a therapy. Allergies are overreactions of the immune system to foreign substances that are normally harmless. Worldwide, and […] August 19, 2022 - 9 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
Interview 19 Aug 2022 Delaying menopause could slow the aging process After decades of neglect, women’s health is attracting increasing interest in the biotech industry. The U.S. startup Oviva Therapeutics aims to develop hormonal therapies that can delay menopause as part of the aging process. Many biotech companies fighting aging are attracting massive cash infusions. One well-known example is Altos Labs, which launched in Silicon Valley […] August 19, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 17 Aug 2022 The challenges of developing radiopharmaceuticals for cancer Radiopharmaceuticals have been a relatively niche area of cancer therapy for decades. Steffen Schuster, the CEO of Germany’s ITM Group, outlines how the space is heating up, and how much nuclear medicine centers still need to grow. There are many areas in oncology research that are generating investor excitement, including immuno-oncology, DNA damage repair and […] August 17, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email